Research
- Sensitivity of 89Zr-labeled anti-CD8 minibody for PET imaging of infiltrating CD8+ T cells (Olafsen et al., AACR 2016)
- An effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy (Tavare et al. 2016 Jan)
- PET Imaging of Cytotoxic Human T cells Using an 89Zr-Labeled Anti-CD8 Minibody
- Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo (Tavare et al. 2014)
- Anti-CD8 immunoPET detection of Cd8+ tumor infiltrating lymphocytes (Tavare et al. WMIC 2014)
- Development of an ImmunoPET Tracer for Imaging Human CD8+ T Cells (Olafsen et al., AACR 2014)
- New PET Imaging Agent Detects Metastatic Prostate Cancer (Dr. Neeta Pandit-Taskar and Dr. Michael J. Morris 2016)
- Comparison Of 89Zr-Df-IAB2M PET/CT To 111 In Capromab Pendetide SPECT/CT In The Detection Of Occult Prostate Cancer In Patients Undergoing Radical Prostatectomy (RP) In a Single Center Phase II Study
- Use of Virtual Dose Reconstruction for Optimization of 89Zr-Df-IAB2M Administered Activity in the Detection of Metastatic Prostate Cancer by PET/CT
- Histopathologic Features that Influence the Detection of Occult Lymph Node Metastasis using PET/CT Imaging with Anti-PSMA 89Zr-Df-IAB2M in Newly Diagnosed High Risk Prostate Cancer Patients
- Head-to-Head Comparison of 89Zr-Df-IAB2M PET/CT to 111 In-CapromabPendetide SPECT/CT Scans in the Detection of Occult Prostate Cancer in Patients Undergoing Radical Prostatectomy (RP) with Negative Conventional Imaging (CI) Studies (M. Gburek et al. 2015)
- Noninvasive Imaging of PSMA in Prostate Tumors with 89Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives (Viola-Villegas et al. 2014)
- 89Zr-Df-IAB2M Minibody Imaging In Patients With Prostate Cancer:Biodistribution, Kinetics, Lesion Uptake And Organ Dosimetry (Dr. Neeta Pandit-Taskar, Dr. Michael Morris et al., SNMMI 2014)
- Multi-Modality Imaging (PET, CLI) of a PSMA-Targeted Cys-Diabody in Tumor-Bearing Mice (Hensley, et al. 2013)
- Optimization of Desferrioxamine Conjugation to a Cytotoxic ADC for In Vivo PET Imaging Studies (Torgov et al., ADC Summit 2014)
- Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody. (Knowles et al. 2014)
- Evaluation of two engineered antibody fragments, derived from the human anti-CD20 Ofatumumab, as tracers for immunoPET (Olafsen et al., AACR 2013)
- ImmunoPET Imaging of Prostate Stem Cell Antigen (PSCA) in Pancreatic Xenografts: Comparison of Intact IgG with Engineered Antibody Fragments (Olafesn et al., SNMMI 2013)
- Nonradioactive Analytical Methods for Quantifying the Modification Ratio of Antibody Fragment Chelator Conjugates with Deferroxamine and NODAGA (Beigarten, Gudas, D. Bartlett 2013)
- Evaluation of Engineered Antibody Fragments Directed to Prostate Stem Cell Antigen (PSCA) in Moderate and Low PSCA Expressing Pancreatic Tumor Xenografts Using PET Imaging (Olafsen, Gudas, Behrenbruch et.al WMIC 2013)
- Positive progress in immunoPET (McCabe, Wu 2010)
- Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2 (Sirk et al. 2008)
- Antibodies for molecular imaging of cancer (Wu, Olafsen, 2008)
- Arming antibodies: prospects and challenges for immunoconjugates (Wu, Senter, 2005)
Presentations
- Annual Advances in Immuno-Oncology USA Congress: Ian Wilson, CEO, presentation titled, “Insights on Reverse Translation for Patient Stratification in Clinical Studies”. Presented Wednesday, October 9, 2019
- Annual Advances in Immuno-Oncology USA Congress: Ian Wilson, CEO, chaired a Panel Discussion titled, “Technological Challenges in Clinical Studies”. Presented Wednesday, October 9, 2019
- Annual Advances in Immuno-Oncology USA Congress hosted by Oxford Global: Ivan Plavec, CBO, webinar titled, “How CD8 Imaging is Useful to Pharma Regarding Drug Research and Clinical Decision Making”. Presented Thursday, August 29, 2019
- SNMMI 2019: Abhinay Joshi gave poster presentation titled, “PET scanner harmonization for multi-center clinical trials using 89Zr tracers in partnership with Clinical Trials Network (CTN)”. Presented Tuesday, June 25, 2019
- SNMMI 2019: Ian Wilson, CEO, presentation titled, “Imaging the Immune System: CD8+ and Beyond ” during the CMIT Emerging Technologies session: Emerging Technologies — A Look into the Future of Molecular Imaging and Therapy”. Presented Sunday, June 23, 2019
- BioEquity Europe 2019: Ian Wilson, CEO, panelist on Panel Discussion titled, “Technologies and Treatments — What’s on the horizon”. Presented Thursday, May 9, 2019
- SITC 2018: Poster and Oral presentation by Michael Gordon on ImaginAb’s Phase I study, titled, “Imaging of tumor-infiltrating T cells with an anti-CD8 minibody 89Zr-IAB22M2C in advanced solid tumors: A phase I first-in-human study”. Presented Friday, November 9, 2018
- WMIC 2018: Tove Olafsen poster presentation titled, “Tracking CD8+ T cells in the Tumor Microenvironment: Development of 89Zr-Df-IAB22M2C, an ImmunoPET Probe for Clinical Immunotherapy Applications”. Presented Friday, September 14, 2018
- SITC 2018: Meeting Abstracts published in Journal for ImmunoTherapy of Cancer 2018 6(Suppl 2):434, Published: December 6, 2018
- SNMMI 2018: Wolfgang Weber gave oral presentation titled, “First-in-Human Phase I Imaging Study with 89Zr-Df-IAB22M2C anti-CD8 minibody in Patients with Solid Tumors”. Presented Saturday, June 23, 2018
- ASCO 2018: Jedd Wolchok presented CD8 PET images from Phase I study as a part of his talk titled, “Immune-Related Response and RECIST in Radiographic Imaging”. Presented Saturday, June 2, 2018
- IO360 2018: Ron Korn presented CD8 PET images from Phase I study as a part of his talk titled, “Use of Imaging Biomarkers for Immunotherapy”. Presented Wednesday, Feb 7, 2018